Evidence map›Paper›PMID 40544300›Full record

ArticleTrials2025

Postoperative Initiation of Thromboprophylaxis in patients with Cushing's Disease (PIT-CD): a randomized controlled trial.

Nidan Qiao, Min He, Zhao Ye, Wei Gong, Zengyi Ma, Yifei Yu, Zhenyu Wu, Lin Lu, Huijuan Zhu, Yong Yao and 16 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04486859 (A Prospective, Multicenter, Randomized Controlled Study of Postoperative Initiation of Thromboprophylaxis in Patients With Cushing's Disease), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04486859 naactive not recruitingnot on this map

A Prospective, Multicenter, Randomized Controlled Study of Postoperative Initiation of Thromboprophylaxis in Patients With Cushing's Disease

TypeinterventionalSponsorHuashan HospitalRan2020 to 2025Enrolled206ConditionsCushing Disease, DVT, Pulmonary EmbolismArmsLMWH/Rivaroxaban, IPC
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Nidan QiaoHuashan Hospital, Shanghai Medical College, Fudan University, Department of Neurosurgery, Shanghai, China. qiaonidan@fudan.edu.cn.ORCID http://orcid.org/0000-0001-5478-3555
Min HeHuashan Hospital, Shanghai Medical College, Fudan University, Department of Endocrinology,, Shanghai, China.
Zhao YeHuashan Hospital, Shanghai Medical College, Fudan University, Department of Neurosurgery, Shanghai, China.
Wei GongHuashan Hospital, Shanghai Medical College, Fudan University, Department of Endocrinology,, Shanghai, China.
Zengyi MaHuashan Hospital, Shanghai Medical College, Fudan University, Department of Neurosurgery, Shanghai, China.
Yifei YuHuashan Hospital, Shanghai Medical College, Fudan University, Department of Endocrinology,, Shanghai, China.
Zhenyu WuFudan University, School of Public Health, Shanghai, China.
Lin LuPeking Union Medical College Hospital, Department of Endocrinology, Beijing, China.
Huijuan ZhuPeking Union Medical College Hospital, Department of Endocrinology, Beijing, China.
Yong YaoPeking Union Medical College Hospital, Department of Neurosurgery, Beijing, China.
Zhihong LiaoThe First Affiliated Hospital, Sun Yat-sen University, Department of Endocrinology, Guangzhou, China.
Haijun WangThe First Affiliated Hospital, Sun Yat-sen University, Department of Neurosurgery, Guangzhou, China.
Huiwen TanChina West Hospital, Department of Endocrinology, Chengdu, China.
Bowen CaiChina West Hospital, Department of Neurosurgery, Chengdu, China.
Yerong YuChina West Hospital, Department of Endocrinology, Chengdu, China.
Ting LeiTongji Hospital, Tongji Medical College, Department of Neurosurgery, Wuhan, China.
Yan YangTongji Hospital, Tongji Medical College, Department of Endocrinology, Wuhan, China.
Changzhen JiangThe First Affiliated Hospital of Fujian Medical University, Department of Neurosurgery, Fuzhou, China.
Xiaofang YanThe First Affiliated Hospital of Fujian Medical University, Department of Endocrinology, Fuzhou, China.
Yanying GuoPeople's Hopital of Xinjiang Uygur Autonomous Region, Department of Endocrinology, Urumqi, China.
Yuan ChenPeople's Hopital of Xinjiang Uygur Autonomous Region, Department of Endocrinology, Urumqi, China.
Hongying YeHuashan Hospital, Shanghai Medical College, Fudan University, Department of Endocrinology,, Shanghai, China.
Yongfei WangHuashan Hospital, Shanghai Medical College, Fudan University, Department of Neurosurgery, Shanghai, China.
Nicholas A TritosMassachusetts General Hospital and Harvard Medical School, Neuroendocrine Unit, Boston, MA, USA.
Zhaoyun ZhangHuashan Hospital, Shanghai Medical College, Fudan University, Department of Endocrinology,, Shanghai, China.
Yao ZhaoHuashan Hospital, Shanghai Medical College, Fudan University, Department of Neurosurgery, Shanghai, China.

Funding

Clinical Research Plan of SHDC SHDC2020CR2004A
6 · The paper itself

Abstract

backgroundPituitary surgical intervention remains the preferred treatment for Cushing's disease (CD) while postoperative venous thromboembolism (VTE) is a significant risk. Whether to prescribe pharmacological thromboprophylaxis presents a clinical dilemma, balancing the benefit of reducing VTE risk with the potential for increasing hemorrhagic events in these patients. Currently, strong evidence and established protocols for routine pharmacological thromboprophylaxis in this population are lacking. Therefore, a randomized, controlled trial is warranted to determine the efficacy and safety of combined pharmacological and mechanical thromboprophylaxis in reducing postoperative VTE risk in patients with CD.

methodsThis investigator-initiated, multi-center, prospective, randomized, open-label trial with blinded outcome assessment aims to evaluate the efficacy and safety of combined pharmacological and mechanical thromboprophylaxis compared to mechanical thromboprophylaxis alone in postoperative patients with CD. A total of 206 patients diagnosed with CD who will be undergoing transsphenoidal surgery will be randomized in a 1:1 ratio to receive either combined pharmacological and mechanical thromboprophylaxis (intervention) or mechanical thromboprophylaxis only (control). The primary outcome is the risk of VTE within 12 weeks following surgery. DISCUSSION: This trial represents a significant milestone in evaluating the efficacy of combined pharmacological and mechanical prophylaxis in reducing VTE events in postoperative CD patients.

trial registrationClinicalTrials.gov Identifier: NCT04486859, first registered on 22 July 2020.

Indexed as

AnticoagulantsPituitary ACTH HypersecretionPostoperative ComplicationsVenous ThromboembolismAdultFemaleHumansMaleMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicRisk FactorsTime FactorsTreatment OutcomeAnticoagulantsCushing’s diseaseDeep vein thrombosisPituitary adenomaPulmonary embolismVenous thromboembolism

Identifiers

PMID40544300
PMCPMC12182689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.